| Type | Condition | Trial / Sponsor | Description |
| Interventional | Solid Tumors | 1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors Mirati Therapeutics, Inc. |
<b>Full Title</b><br> 1719-001: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion <br><br> <b>Study Treatment</b><br> Oral PRMT5 inhibitor MRTX1719 <br><br> <b>Eligibility/Info</b><br> Phase 1 - advanced MTAP deleted solid tumor that has continued to grow despite treatment with standard anti-cancer therapies. <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Non-Small Cell Lung Cancer | ARTEMIA: Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor OSE Immunotherapeutics |
<p> <b>Full Title</b><br> Protocol OSE2101C302: A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor </p> <p> <b>Study Treatment</b><br> OSE2101, a peptidic cancer vaccine, given in combination with chemotherapeutic agent docetaxel </p> <p> <b>Eligibility/Info</b><br> Participants must have a history of an advanced/metastatic non-small cell lung cancer that has progressed after at least 24 weeks of first line treatment with immunotherapy. </p> <p> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Breast Cancer | ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer Gilead Sciences, Inc. |
<b>Full Title</b><br> Protocol GS-US-595-6184: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy <br><br> <b>Study Treatment</b><br> Arm A: Anti-TROP2 antibody-drug conjugate sacituzumab govitecan + pembrolizumab<br> Arm B: pembrolizumab +/- capecitabine <br><br> <b>Eligibility/Info</b><br> Non-metastatic triple negative breast cancer treated with neoadjuvant systemic therapy followed by surgery. <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Cachexia | AV-380-22-102: A Dose Escalation Study of GDF-15 Inhibitor AV-380 in Metastatic Cancer Patients with Cachexia AVEO Pharmaceuticals, Inc. |
<b>Full Title</b><br> AV-380-22-102: A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels <br><br> <b>Study Treatment</b><br> Intravenous GDF-15 inhibitor AV-380 <br><br> <b>Eligibility/Info</b><br> Advanced or metastatic cancer currently being treated with standard of care systemic therapy. Must have cachexia as defined by the Fearon criteria as one of:<br> - Weight loss >5% over past 6 months (in absence of simple starvation), or<br> - BMI < 20 kg/m<sup>2</sup> and any degree of weight loss >2%, or<br> - Sarcopenia and >2% weight loss <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Colon Cancer | AZUR-2: Perioperative Dostarlimab in Patients with dMMR/MSI-H Resectable Colon Cancer GlaxoSmithKline |
<b>Full Title</b><br> Protocol 219606: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer <br><br> <b>Study Treatment</b><br> Perioperative treatment with anti-PD1 monoclonal antibody dostarlimab <br><br> <b>Eligibility/Info</b><br> - Pathologically confirmed resectable (T4N0 or Stage III) colon adenocarcinoma<br> - Mismatch repair deficient or MSI-High<br> - No history of treatment <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Non-Small Cell Lung Cancer | AndroMETa-Lung-536: Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC AbbVie |
<p> <b>Full Title</b><br> Protocol M24-536: An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations </p> <p> <b>Study Treatment</b><br> c-MET targeting antibody-drug conjugate telisotuzumab adizutecan in combination with investigational anti-PD-1 antibody budigalimab or standard chemo/immunotherapy. </p> <p> <b>Eligibility/Info</b><br> <p> Part 2: Participants must have had no prior systemic therapy for locally advanced or metastatic NSCLC. </p> </p> <p> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Breast Cancer | Breast Cancer | BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer BriaCell Therapeutics Corporation |
<b>Full Title</b><br> BC-IMT-04: Randomized, Open-label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer <br><br> <b>Study Treatment</b><br> GM-CSF-secreting breast cancer vaccine SV-BR-1-GM in combination with anti-PD1 immunotherapy retifanlimab-dlwr <br><br> <b>Eligibility/Info</b><br> Eligible patients will have one of the following prior treatment histories: <br> - <u>HR+/HER2-</u>: Previously treated with at least 2 prior chemotherapy or targeted therapy regimens<br> - <u>HER2+</u>: Previously treated with at least 3 treatment regimens including 2 anti-HER2 therapies<br> - <u>TNBC</u>: Exhausted all standard of care therapies known to confer clinical benefit<br> - <u>HER2-Low</u>: Previously treated with at least 1 anti-HER2 therapy in addition to the appropriate HR status therapies<br> - <u>Actionable Mutation</u>: Patients with an actionable mutation must have been treated with appropriate targeted therapy <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Non-Small Cell Lung Cancer | COPERNICUS: A Phase 2b, Open-Label, Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment Janssen Research & Development, LLC |
<p> <b>Full Title</b><br> Protocol 61186372NSC2012: A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer </p> <p> <b>Study Treatment</b><br> Amivantamab, a bispecific antibody targeting EGFR and MET in combination with lazertinib, an EGFR tyrosine kinase inhibitor. </p> <p> <b>Eligibility/Info</b><br> Eligible patients will have an advanced/metastatic non-small cell lung cancer with an EGFR exon 19 deletion or EGFR L858R mutation and will not have received systemic anticancer therapy in the advanced/metastatic setting. </p> <p> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Observational | Non-Small Cell Lung Cancer | CYBRID-01: Observational lung trial to collect tissue to train and validate a live tumor diagnostic platform Elephas Biosciences Corporation |
<b>Full Title</b><br> Protocol ELEP-2022-CYBRID-01: Observational lung trial to collect tissue to train and validate a live tumor diagnostic platform <br><br> <b>Study Treatment</b><br> The study includes one scheduled on-site visit for baseline enrollment. Biopsy(ies) will be collected from all enrolled subjects. The biopsy should be collected as an additional pass(es) during a standard of care core needle biopsy. <br><br> <b>Eligibility/Info</b><br> - Patients with suspected metastatic non-small cell lung cancer that will be undergoing a core biopsy at the Lake Success Medical Oncology office. <br><br> Elephas will train and validate its cancer diagnostic platform for prediction of drug response, with a focus on the checkpoint inhibitor pembrolizumab (Keytruda). <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Multiple Myeloma | Cervino: Study of Treatment with Bispecific Antibody ABBV-383 in Relapsed/Refractory Multiple Myeloma After at Least 2 Prior Lines of Therapy AbbVie |
<b>Full Title</b><br> Protocol M22-574: A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) <br><br> <b>Study Treatment</b><br> BCMAxCD3 bispecific antibody ABBV-383 vs standard approved therapy <br><br> <b>Eligibility/Info</b><br> Relapsed/refractory multiple myeloma treated with at least 2 prior lines of therapy. Prior therapy must have included an immunomodulating agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a> |
| Just In Time | Central Nervous System Cancer | F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy Fore Biotherapeutics |
<b>Full Title</b><br> F8294-201b: A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations <br><br> <b>Study Treatment</b><br> Oral BRAF inhibitor FORE8394 in combination with cobicistat <br><br> <b>Eligibility/Info</b><br> For the treatment of patients with a BRAF V600E mutant CNS primary malignancy that has recurred or continued to grow after at least 1 prior line of therapy including radiation. <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" |
| Interventional | Breast Cancer | First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer Regor Pharmaceuticals Inc. |
<b>Full Title</b><br> First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer <br><br> <b>Study Treatment</b><br> RGT-419B, an oral CDK2/4/6 inhibitor <br><br> <b>Eligibility/Info</b><br> - HR+, HER2- breast cancer with progressive disease after at least 1 line of therapy including a CDK4/6 inhibitor <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Colorectal Cancer | INTRINSIC: A Multi-Arm Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer Hoffmann-La Roche |
<p> <b>Full Title</b><br> Protocol WO42758: A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer </p> <p> <b>Study Treatment</b><br> Oral KRAS G12C inhibitor Divarasib in combination with standard of care chemotherapy regimen FOLFOX or FOLFIRI </p> <p> <b>Eligibility/Info</b><br> <ul> <li>Stage IV colon or rectal adenocarcinoma</li> <li>KRAS G12C mutation and the absence of another oncogenic mutation</li> <li>No prior systemic therapy in the advanced/metastatic setting</li> </ul> </p> <p> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Non-Small Cell Lung Cancer | KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation Mirati Therapeutics, Inc. |
<b>Full Title</b><br> Protocol 849-017: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation <br><br> <b>Study Treatment</b><br> KRAS G12C inhibitor adagrasib in combination with standard chemo/immunotherapy. <br><br> <b>Eligibility/Info</b><br> Unresectable or metastatic KRAS G12C mutant non-squamous non-small cell lung cancer that has not been treated in the metastatic setting. <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Breast Cancer | MoonROSE: CDK2/4/6 Inhibitor GDC-4198 in Combination with Giredestrant for Patients with ER+, HER2- Metastatic Breast Cancer After Treatment with a CDK4/6 Inhibitor Genentech, Inc. |
<p> <b>Full Title</b><br> Protocol GO46021: A Phase Ib/II Multicenter, Open-label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2-negative Breast Cancer Who Have Previously Progressed During Or After a CDK4/6 Inhibitor </p> <p> <b>Study Treatment</b><br> Oral CDK2/4/6 inhibitor GDC-4198 as monotherapy or in combination with oral next generation SERD Giredestrant </p> <p> <b>Eligibility/Info</b><br> Eligible patients must have metastatic ER+, HER2- breast cancer that has been treated with a CDK4/6 inhibitor in the metastatic setting but has not been treated with chemotherapy in the metastatic setting. </p> <p> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Colorectal Cancer | OrigAMI-2: Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Cancer Janssen Research & Development, LLC |
<p> <b>Full Title</b><br> Protocol 61186372COR3001: A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer </p> <p> <b>Study Treatment</b><br> EGFRxMET bispecific antibody Amivantamab vs Cetuximab<br> Given in combination with either FOLFOX or FOLFIRI chemotherapy </p> <p> <b>Eligibility/Info</b><br> KRAS, NRAS, and BRAF wild type unresectable or metastatic left sided colorectal cancer that has not previously been treated with systemic therapy in the metastatic setting. </p> <p> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Colorectal Cancer | OrigAMI-3: Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Janssen Research & Development, LLC |
<p> <b>Full Title</b><br> Protocol 61186372COR3002: A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy </p> <p> <b>Study Treatment</b><br> EGFRxMET bispecific antibody Amivantamab vs Cetuximab or Bevacizumab<br> Given in combination with the FOLFIRI chemotherapy regimen </p> <p> <b>Eligibility/Info</b><br> KRAS, NRAS, and BRAF wild type unresectable or metastatic colorectal cancer previously treated with a fluoropyrimidine and oxaliplatin in the metastatic setting and with no history of treatment with an EGFR inhibitor or irinotecan. </p> <p> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Chronic Myeloid Leukemia | POLARIS-2: Study of Olverembatinib (HQP1351) in Patients With CP-CML Ascentage Pharma Group Inc. |
<p> <b>Full Title</b><br> Protocol HQP1351CG301: A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia </p> <p> <b>Study Treatment</b><br> Third-generation BCR-ABL1 tyrosine kinase inhibitor Olverembatinib vs bosutinib </p> <p> <b>Eligibility/Info</b><br> Eligible patient must have chronic phase chronic myeloid leukemia without a history of accelerated or blastic phase. <br> Part A: Treatment with at least two prior TKIs and confirmed absence of T315I and V229L mutations<br> Part B: Confirmed presence of T315I mutation, prior treatment with at least 1 TKI, and lack of other effective/tolerable therapies </p> <p> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/nostrand_medical_oncology">Nostrand Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Advanced Solid tumors | Phase 1 Study of SGN-B6A in Advanced Solid Tumors Seagen Inc. |
<b>Full Title</b><br> A Phase 1 Study of SGN-B6A in Advanced Solid Tumors This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. <br><br> <b>Study Treatment</b><br> The study will have enroll in unique cohorts:<br><br> <br><br> <b>Part D</b> will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors.<br> Combination therapy in 1L NSCLC<br> Sigvotatug vedotin + pembrolizumab (Keytruda) +/- (carboplatin)<br> <br><br> <b>Eligibility/Info</b><br> • Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on study part).<br> • Non-small cell lung cancer (NSCLC)<br> • Head and neck squamous cell cancer (HNSCC)<br> • Advanced HER2-negative breast cancer<br> • Esophageal squamous cell carcinoma (ESCC)<br> • Esophageal/Gastro-esophageal junction adenocarcinoma (EAC/GEJ)<br> • Cutaneous squamous cell cancer (cSCC)<br> • Exocrine pancreatic adenocarcinoma<br> • Bladder cancer<br> • Cervical cancer<br> • Gastric cancer<br> • High grade serous ovarian cancer (HGSOC)<br> • Participants should have a tumor site accessible for biopsy or archival biopsy collected within 90 days prior to first dose of study drug may be used.<br> • Measurable disease per the RECIST v1.1 at baseline<br> Exclusion Criteria<br> • History of another malignancy within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.<br> • Known active central nervous system metastases. <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Interventional | Solid Tumors or Multiple Myeloma | QXL138AM-001: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma Nammi Therapeutics Inc |
<p> <b>Full Title</b><br> Protocol QXL138AM-001: A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma </p> <p> <b>Study Treatment</b><br> QXL138AM is interferon alpha 2 (IFNα2) masked immunocytokine (MIC) fused to antibody targeting CD138 </p> <p> <b>Eligibility/Info</b> <ul> <li><b>Solid tumors</b>: Metastatic ovarian, pancreatic, urothelial, renal, gastrointestinal (GI), lung, prostate, or breast cancer that has continued to grow after standard systemic therapies.</li> <li><b>Multiple Myeloma</b>: Multiple myeloma that has continued to grow after treatment with at least 3 lines of therapy that included an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulating agent. </li> </ul> </p> <p> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p> |
| Interventional | Non-Small Cell Lung Cancer | TeLuRide-005: EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer Eikon Therapeutics |
<b>Full Title</b><br> EIK1001-005: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer <br><br> <b>Study Treatment</b><br> Toll-Like Receptor 7 and 8 co-agonist, EIK1001 given in combination with chemotherapy and pembrolizumab <br><br> <b>Eligibility/Info</b><br> - Stage IV squamous or non-squamous non-small cell lung cancer<br> - No history of systemic therapy in the advanced/metastatic setting<br> - No actionable mutation <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> |
| Non-Interventional | Cancer Diagnosis | [Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients Memorial Sloan Kettering Cancer Center |
<b>Full Title</b><br> Protocol 12-245: Genomic Profiling in Cancer Patients <br><br> <b>Description</b><br> Genetic testing for patients with a cancer diagnosis or that are undergoing a work up to establish a potential cancer diagnosis. The primary objective of the trial is to determine the frequency of “actionable” oncogenic mutations in patients with solid or hematologic cancers being evaluated for treatment. <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" |
| Non-Interventional | Various Indications | [Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) Precision for Medicine |
<b>Full Title</b><br> Protocol PMDx060: Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" |
| Non-Interventional | Solid Tumors | [Sample Collection] Collection and Distribution of Biofluids for Research Purposes Bluestar Genomics |
<b>Description</b><br> Blood sample collection study for patients with newly diagnosed, untreated solid tumors excluding prostate and melanoma. <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" |
| Non-Interventional | Solid Tumors | [Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2) Exact Sciences Thrive LLC |
<b>Full Title</b><br> Protocol THR-CS-001: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) <br><br> <b>Eligibility</b><br> Observational, sample collection study for patients with a new, untreated diagnosis of one of the following malignancies: <br> Breast, lung, colorectal, bladder, uterine, kidney/renal pelvis, pancreatic, liver, stomach, ovarian, esophageal cancer, head and neck squamous cell, thyroid, small intestine, cervical, anal, vulva, or testis <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" |
| Non-Interventional | Various Indications | [Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) SERATRIALS, LLC. |
<b>Full Title</b><br> Protocol SeraTrials-05035 - Blood sample collection study with constantly changing set of available cohorts. <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" |
| Non-Interventional | Solid Tumors | [Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening Freenome Holdings Inc. |
<b>Full Title</b><br> Protocol FRM-008: The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening <br><br> <b>Eligibility/Info</b><br> Blood draw study for patients with solid tumors that have not yet received treatment. <br><br> Freenome is developing blood-based screening tests for multiple cancer types using its multiomics platform. The current protocol targets enrolling subjects with specified types of cancers... for the development of multicancer products. <br><br> <b>Contact</b><br> For more information about this or any other study, please contact the NYCBS Research Department:<br> Email: <a href="mailto:ResearchRecruitment@nycancer.com">ResearchRecruitment@nycancer.com</a><br> Telephone: <a href="tel:631-675-5075">631-675-5075</a><br> HALO Messaging App: "Research Team" |